INBP — Integrated Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $6.47m
- $5.77m
- $50.67m
- 66
- 94
- 13
- 59
Annual cashflow statement for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1.69 | 4.11 | 8.01 | 3.84 | -0.034 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.716 | 0.377 | -0.869 | 0.882 | 1.15 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.43 | -2.11 | -3.05 | 0.565 | -0.302 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 0.328 | 1.34 | 3.05 | 4.09 | 1.23 |
| Capital Expenditures | -0.414 | -0.214 | -0.295 | -0.486 | -0.116 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.008 | 0.104 | 0.096 | 0.021 | 0.005 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.422 | -0.11 | -0.199 | -0.465 | -0.111 |
| Financing Cash Flow Items | 0.233 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.341 | -1.3 | -3.04 | -3.5 | -0.136 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.247 | -0.073 | -0.192 | 0.121 | 0.985 |